Ampersand Capital Partners portfolio company Avista Pharma Solutions (APS) has acquired Solid Form Solutions Limited (SFS).

The target company will operate from Edinburgh, Scotland, following the acquisition.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The acquisition will strengthen APS’s solid phase chemistry services.

Based in the UK, APS is a contract development and manufacturing organisation, while SFS is also based in the UK and involved in providing solid-state chemistry and crystallisation development services.

“The acquisition will help Venn Life Sciences Holdings to reinforce its data management and clinical capabilities.”

Venn Life Sciences Holdings Plc has increased its stake in Venn Life Sciences (France) SAS (VLSF) to 100% by acquiring the remaining 11.03% stake in the target company from Christian Le Bras (CLB).

CLB will continue to operate as head of interactive response technology in VLS, following the acquisition.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The acquisition will help Venn Life Sciences Holdings to reinforce its data management and clinical capabilities.

Both companies are clinical research organisations based in France.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact